| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.1 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.066 | 0.1 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.1 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.1 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.082 | 0.1 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | JW-7-24-1 | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |